Long-term efficacy of the sublingual and subcutaneous routes in allergen immunotherapy
Authors:
- Martin PenagosMPMartin Penagos
- Stephen R. DurhamSDStephen R. Durham
- 1 July 2022
- journal article
- research article
- Published by Oceanside Publications Inc. in Allergy and Asthma Proceedings
- Vol. 43 (4) , 292-298
Abstract
Allergen immunotherapy is highly effective in selected patients with allergic rhinitis, allergic asthma, and Hymenoptera venom allergy. Unlike anti-allergic drugs, both subcutaneous and sublingual immunotherapies have been shown to modify the underlying cause of the disease, with proved long-term clinical benefits after treatment cessation. In this review, we analyzed 10 randomized, double-blind, placebo controlled clinical trials of allergen immunotherapy that included blinded follow-up for at least 1 year after treatment withdrawal. Three studies of pollen subcutaneous immunotherapy provided evidence that a sustained, tolerogenic effect of subcutaneous immunotherapy can be achieved after 3 years of treatment. Six trials of sublingual immunotherapy provided robust evidence for long-term clinical benefit and persistent immunologic changes after grass pollen, house-dust mite, or Japanese cedar immunotherapy, whereas a clinical trial of both sublingual and subcutaneous grass pollen immunotherapies showed that 2 years of immunotherapy were efficacious but insufficient to induce long-term tolerance. These studies strongly supported international guidelines that recommend at least 3 years of allergen immunotherapy of proven value to achieve disease modification and sustained clinical and immunologic tolerance.Keywords
This publication has 27 references indexed in Scilit:
- SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trialJournal of Allergy and Clinical Immunology, 2012
- Allergen immunotherapy: A practice parameter third updateJournal of Allergy and Clinical Immunology, 2011
- Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT studyAllergy, 2009
- Specific immunotherapy has long‐term preventive effect of seasonal and perennial asthma: 10‐year follow‐up on the PAT studyAllergy, 2007
- Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforceAllergy, 2007
- Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitisJournal of Allergy and Clinical Immunology, 2006
- Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitisJournal of Allergy and Clinical Immunology, 2006
- Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthmaJournal of Allergy and Clinical Immunology, 2006
- Long‐term treatment with allergoid immunotherapy with Parietaria. Clinical and immunologic effects in a randomized, controlled trialAllergy, 1999
- Clinical aspects of allergic disease: A double-blind study of the discontinuation of ragweed immunotherapyJournal of Allergy and Clinical Immunology, 1997